INTS
Intensity Therapeutics, Inc.NASDAQHealthcare$5.70-3.67%ClosedMarket Cap: $10.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
6.27
P/S
0.00
EV/EBITDA
0.16
DCF Value
$0.84
FCF Yield
-89.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-214.8%
ROA
-82.3%
ROIC
-99.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-3.1M | $-3.1M | $-1.21 | — |
| FY 2025 | $0.00 | -Infinity% | $-12.0M | $-11.6M | $-8.56 | — |
| Q3 2025 | $0.00 | -Infinity% | $-2.7M | $-2.7M | $-1.55 | — |
| Q2 2025 | $0.00 | NaN% | $-2.7M | $-2.5M | $-3.25 | — |
| Q1 2025 | $0.00 | NaN% | $-3.4M | $-3.3M | $-5.50 | — |
| Q4 2024 | $0.00 | NaN% | $-3.2M | $-3.2M | $-5.50 | — |
| FY 2024 | $0.00 | NaN% | $-16.6M | $-16.3M | $-29.25 | — |
| Q3 2024 | $0.00 | NaN% | $-3.6M | $-3.5M | $-6.25 | — |
| Q2 2024 | $0.00 | NaN% | $-5.1M | $-5.0M | $-9.00 | — |
| Q1 2024 | $0.00 | -Infinity% | $-4.7M | $-4.6M | $-8.50 | — |
| Q4 2023 | $0.00 | NaN% | $-3.4M | $-3.2M | $-5.75 | — |
| FY 2023 | $0.00 | -Infinity% | $-8.3M | $-10.5M | $-34.50 | — |